Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture

Author(s): Jose L. Perez-Castrillon, Isabel Justo, Alberto Sanz-Cantalapiedra, Carol Pueyo, Gonzalo Hernandez, Antonio Duenas

Journal Name: Current Hypertension Reviews

Volume 1 , Issue 1 , 2005

Become EABM
Become Reviewer


The financial and social cost of hypertension and osteoporosis, clinically silent diseases, are determined by the consequences, such as a vascular disease and fractures. The relationship between these illnesses has not been clearly established, although many alterations in extracellular metabolism of calcium, which could determine the level of bone mineral density (BMD) in these patients, have been associated to hypertension. Despite these alterations, the lack of studies relating these two important diseases is surprising, and hypertension is not identified as a risk factor for osteoporosis. Interestingly, there is a lack of information of the long-term effects of antihypertensive treatment on bone mineral density, although 50 % of the hypertensive population is made up of postmenopausal women. Most studies analyzed the effects of thiazides and, to a lesser degree, the effects of calcium antagonist. The purpose of this review is evaluate the effect of the antihypertensive therapeutic group (diuretics, β-blockers, calcium antagonists, angiotensin converting enzyme) on the bone mineral density (BMD) and osteoporotic fracture.

Keywords: hypertension, osteoporosis, thiazides, bloqueantes, antagonistas del clacio, aceis

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [61 - 66]
Pages: 6
DOI: 10.2174/1573402052952843

Article Metrics

PDF: 15